Premium
Hydroxyurea use in prevention of stroke recurrence in children with sickle cell disease in a developing country: A cost effectiveness analysis
Author(s) -
CunninghamMyrie Colette,
Abdulkadri Abdullahi,
Waugh Andre,
Bortolusso Ali Susanna,
King LesleyGaye,
KnightMadden Jennifer,
Reid Marvin
Publication year - 2015
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.25563
Subject(s) - medicine , stroke (engine) , disease , blood cancer , pediatrics , cost effectiveness , cause of death , cancer , mechanical engineering , risk analysis (engineering) , engineering
We undertook a cost effectiveness analysis (CEA) of hydroxyurea (HU) in preventing stroke recurrence and/or death. We followed 43 children with sickle cell disease from 2000 to 2009 after having a first clinical stroke, of whom 10 opted for HU therapy. HU use led to decreased stroke recurrence and death without significantly increasing the annual cost of care per patient (J$83,250 vs. J$76,901, P = 0.491). The incremental cost effectiveness ratio (ICER) for prevention of stroke recurrence amounted to J$169,238 (US$1,900), while that for death prevention equalled J$635,843 (US$7,140). HU may be recommended when safe and affordable transfusion therapy is not feasible. Pediatr Blood Cancer 2015;62:1862–1864. © 2015 Wiley Periodicals, Inc.